France prostate cancer diagnostic and therapeutic market was valued at $476.5 million in 2025 and is projected to reach $959.6 million by 2035, growing at a CAGR of 7.3% during the forecast period (2026-2035). The accelerating adoption of AI-enabled digital pathology platforms across leading oncology centers is emerging as a key growth driver in the market. In October 2025, Aiforia Technologies Plc announced that Institute Curie selected its CE-IVD marked clinical AI solutions to support breast and prostate cancer diagnostics. The agreement reflects a broader institutional shift toward integrating validated, regulatory-compliant AI tools directly into routine pathology workflows. By deploying a multi-model AI platform that supports the entire diagnostic pathway, hospitals are strengthening accuracy, speed, and consistency in tumor grading and classification, which directly influences treatment planning.
Browse the full report description of “France Prostate Cancer Diagnosis & Treatment Market Size, Share & Trends Analysis Report by Diagnostic Technique (Prostate Specific Antigen Test, Digital Rectal Exam), by Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy) Forecast Period, 2026–2035” at https://www.omrglobal.com/industry-reports/france-prostate-cancer-diagnostic-therapeutic-market
The partnership is particularly significant given Institute Curie’s position as one of France’s leading cancer centers with advanced digital pathology capabilities across multiple sites. Adoption at this level signals rising clinical confidence in AI-assisted diagnostics, especially in high-incidence cancers such as prostate cancer where histopathological interpretation plays a decisive role in risk stratification. As healthcare systems across Europe face increasing cancer burden and specialist shortages, AI-powered diagnostic platforms help optimize laboratory throughput while reducing inter-observer variability. This enhances standardization of Gleason grading and supports more precise therapeutic decision-making, thereby stimulating demand for complementary imaging agents, targeted therapies, and minimally invasive treatment modalities.
Such collaborations also demonstrate growing regulatory alignment and reimbursement support for AI-driven diagnostic tools. The CE-IVD certification ensures compliance with European in vitro diagnostic standards, improving scalability across EU markets. Furthermore, Aiforia’s expansion through a local French subsidiary indicates strategic geographic penetration in high-value oncology markets. These developments collectively reinforce a structural transition toward digitally integrated oncology ecosystems, positioning AI-assisted pathology as a foundational enabler of sustainable growth in the prostate cancer diagnostic and therapeutic landscape.
Key Leaders Transforming the France Prostate Cancer Diagnostic and Therapeutic Market
The key players in the France prostate cancer diagnostic and therapeutic market include Astellas Pharma Inc., Pfizer Inc., Johnson & Johnson, Novartis AG, F. Hoffmann-La Roche AG, among others. These companies are driving innovation in the prostate cancer market through the development of next-generation immunotherapies, PSMA-targeted radiopharmaceuticals, precision imaging agents, and advanced molecular diagnostic platforms. Their focus on improving treatment efficacy, enhancing safety profiles, enabling earlier and more accurate detection, and supporting personalized therapy approaches is accelerating progress in advanced and metastatic prostate cancer care across global healthcare markets.
Market Coverage
Key questions addressed by the report.
France Prostate Cancer Diagnostic and Therapeutic Market Report Segment
By Diagnostic Technique
By Therapeutics
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/france-prostate-cancer-diagnostic-therapeutic-market